THERAPY DOSSIER · th-adecac0aa0d4

Skin-derived precursors pre-differentiated into Schwann cells (SKP-SCs)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24440805 ↗2014Reported benefit

Skin derived precursor Schwann cells improve behavioral recovery for acute and delayed nerve repair.

RatOtherLewis (inbred)Male and femalen = 90 rats in the pre-clinical trial; follow-up at 4, 8, 17 an…Injection into the graft or distal to the repair siteAt acute repair, and at delayed repair 11 weeks after transection

Model: Sciatic nerve injury with acellular graft repair, and tibial nerve transection with acute or delayed (11 week) direct repair

SKP-SC treatment gave significantly better ladder-rung performance than all other groups after graft repair, improvement from 5 weeks after acute repair, and significant improvement from 7 weeks after delayed repair. Axon counts were higher and myelin debris lower at 4 and 8 weeks, with improved co…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…